Recent Advances in Artificial Intelligence Systems Are Now Providing a Basis for the Introduction of Greater Automation
SMi Reports: Hear from Gisbert Scnieder, Professor, Chair for Computer-Assisted Drug Design, ETH Zurich at SMi's Drug Discovery Conference in March
London, United Kingdom, February 02, 2018 --(PR.com)-- Small-molecule drug discovery can be viewed as a challenging multidimensional problem in which various characteristics of compounds — including efficacy, pharmacokinetics and safety — need to be optimized in parallel to provide drug candidates. Recent advances in areas such as artificial intelligence systems that improve a design hypothesis through feedback analysis, are now providing a basis for the introduction of greater automation into aspects of this process. This could potentially accelerate time frames for compound discovery and optimization and enable more effective searches of chemical space. However, such approaches also raise considerable conceptual, technical and organizational challenges, as well as scepticism about the current hype around them (Gisbert Scnieder, 2017).
Hear more from Gisbert Scnieder at SMi's Drug Discovery conference taking place in London on 21st and 22nd March 2018. Mr Scnieder will discuss "Artificially Intelligent Drug Design": De Novo Compound Design in Silico; Target Prediction and Off-Target Profiling; Automating Drug Discovery by Machine Learning. Exscientia, BenevolentAI and AstraZeneca will also be presenting on Artificial Intelligence in Drug Discovery.
SMi are additionally hosting two pre-conference workshops on Tuesday 20th March which will be lead by Axol Bioscience and AstraZeneca. Get to understand the revolutionary biological technique of creating induced pluripotent stem cells (iPSC) from any source material. Learn about sourcing of healthy and disease cells from patient material, including possible ethical and consensual pitfalls. Learn a historical perspective of reprogramming technology and the fundamentals of turning cells into the iPSC state. Learn how to use CRISPR/CAS9 to create disease models in iPSCs. Learn from AstraZeneca’s UK Lead for Genome Editing / CRISPR on how genome editing has revolutionised drug development and so much more!.
For more details about the conference and registration information, visit www.drug-discovery.co.uk/prcom
Drug Discovery
21st – 22nd March 2018
Copthorne Tara Hotel, London, UK
www.drug-discovery.co.uk/prcom
Contact Information:
For sponsorship and exhibition queries please contact Alia Malick at amalick@smi-online.co.uk. For delegate queries please contact Kieran Ronaldson at kronaldson@smi-online.co.uk. For media queries please contact Natasha Boumediene at nboumediene@smi-online.co.uk.
About SMi Group:
Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world’s most forward thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk
Hear more from Gisbert Scnieder at SMi's Drug Discovery conference taking place in London on 21st and 22nd March 2018. Mr Scnieder will discuss "Artificially Intelligent Drug Design": De Novo Compound Design in Silico; Target Prediction and Off-Target Profiling; Automating Drug Discovery by Machine Learning. Exscientia, BenevolentAI and AstraZeneca will also be presenting on Artificial Intelligence in Drug Discovery.
SMi are additionally hosting two pre-conference workshops on Tuesday 20th March which will be lead by Axol Bioscience and AstraZeneca. Get to understand the revolutionary biological technique of creating induced pluripotent stem cells (iPSC) from any source material. Learn about sourcing of healthy and disease cells from patient material, including possible ethical and consensual pitfalls. Learn a historical perspective of reprogramming technology and the fundamentals of turning cells into the iPSC state. Learn how to use CRISPR/CAS9 to create disease models in iPSCs. Learn from AstraZeneca’s UK Lead for Genome Editing / CRISPR on how genome editing has revolutionised drug development and so much more!.
For more details about the conference and registration information, visit www.drug-discovery.co.uk/prcom
Drug Discovery
21st – 22nd March 2018
Copthorne Tara Hotel, London, UK
www.drug-discovery.co.uk/prcom
Contact Information:
For sponsorship and exhibition queries please contact Alia Malick at amalick@smi-online.co.uk. For delegate queries please contact Kieran Ronaldson at kronaldson@smi-online.co.uk. For media queries please contact Natasha Boumediene at nboumediene@smi-online.co.uk.
About SMi Group:
Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world’s most forward thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk
Contact
SMi Group
Natasha Boumediene
+44 (0) 207 827 6020
www.drug-discovery.co.uk/prcom
Natasha Boumediene
+44 (0) 207 827 6020
www.drug-discovery.co.uk/prcom
Contact
Categories